Osteoarthritis - Pipeline Review, H2 2017; New Report Launched

Bangalore, India -- (SBWire) -- 10/20/2017 --Osteoarthritis - Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights
Osteoarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 240 pages "Osteoarthritis - Pipeline Review, H2 2017" report covers Introduction, Osteoarthritis - Overview, Osteoarthritis - Therapeutics Development, Osteoarthritis - Therapeutics Assessment, Osteoarthritis - Companies Involved in Therapeutics Development, Osteoarthritis - Drug Profiles, Osteoarthritis - Dormant Projects, Appendix. This report Covered Companies few are - Biopharm GmbH, Bone Therapeutics SA, Can-Fite BioPharma Ltd, Cardax Inc, Cellular Biomedicine Group Inc, Corestem Inc, Dong-A Socio Holdings Co Ltd, Eli Lilly and Company, Evgen Pharma Plc, Galapagos NV, Gemphire Therapeutics Inc.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/osteoarthritis-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/t-cell-surface-glycoprotein-cd3-epsilon-chain-t-cell-surface-antigen-t3leu-4-1

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/cytotoxic-t-lymphocyte-protein-4-cytotoxic-t-lymphocyte-associated-antigen-4-0

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.